|
COPYRIGHT 2005 International Medical News Group
GLASGOW, SCOTLAND -- In the first phase III trial evaluating infliximab for plaque psoriasis, substantial improvements were achieved by week 10 and sustained through week 50 in the majority of patients, Kristian Reich, M.D., said at the annual meeting of the British Association of Dermatologists.
The 281 patients who were randomized to receive either placebo or infusions of infliximab, 5 mg/kg at week 0, 2, and...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
